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Abstract
Problem: As o f  D ecem ber 31, 200 8 , an estim ated  6 6 3 ,0 8 4  persons w ere living w ith  a diagnosis o f  h u m a n  im m unodefic iency  
virus (H IV ) in fec tion  in  th e  40  U .S. states th a t have had  confiden tia l nam e-based  H IV  in fec tion  rep o rtin g  since at least January  
2 0 0 6 . A lth o u g h  H IV  surveillance program s in  the  U n ite d  States collect in fo rm atio n  ab o u t persons w ho have received a diagnosis 
o f  H IV  in fec tion  an d  acquired  im m unodefic iency  syndrom e (A ID S), supp lem en tal surveillance projects are needed  to  collect 
in fo rm ation  ab o u t care-seeking behaviors, health-care use, and  o th e r behaviors am ong  persons living w ith  HIV . D a ta  on  the clinical 
an d  behavioral characteristics o f  persons receiving m edical care for H IV  in fec tion  are critical to  reduce H IV -re la ted  m o rb id ity  
an d  m o rta lity  and  for p rog ram  p lan n in g  to  allocate services and  resources, guide p reven tion  p lann ing , assess u n m e t m edical and 
ancillary service needs, an d  help  develop in te rv en tio n  program s an d  hea lth  policies at the local, state , an d  national levels.
Reporting Period Covered: D a ta  w ere collected d u rin g  June  2 0 0 7 —S eptem ber 2008  for patien ts w ho received m edical care in 
2 0 0 7  (sam pled from  January  1—A pril 30).
Description ofthe System: T h e  M edical M o n ito rin g  Project (M M P) is an ongoing, m ultisite supplem ental surveillance project that 
assesses behaviors, clinical characteristics, and  quality  o f  care o f  H IV -in fec ted  persons w ho are receiving m edical care. P articipants 
m ust be aged >18 years and  have received m edical care at sam pled  facilities th a t prov ide H IV  m edical care w ith in  partic ipa ting  
M M P  pro jec t areas. Self-reported  behavioral and  selected clinical d a ta  are collected using an  in -person  interview . A  to ta l o f  26 
p ro jec t areas in  19 states and  P uerto  Rico w ere funded  to  collect d a ta  d u rin g  the 2 0 0 7  M M P  d ata  co llection  cycle.
Results: T h e  results from  th e  2 0 0 7  M M P  cycle ind icated  th a t am ong  3 ,643  partic ipan ts, a to ta l o f 3 ,0 4 0  (84% ) had  som e form  o f  
h ea lth  insurance or coverage d u rin g  th e  12 m o n th s  before the  in terview ; o f  these, 4 5 %  repo rted  hav ing  M edicaid , 37%  reported  
hav ing  private h ea lth  insurance o r coverage th ro u g h  a h ea lth  m ain tenance  organization , and  30%  repo rted  hav ing  M edicare. A 
to ta l o f 3 ,091 (85% ) o f  the partic ipan ts w ere cu rren tly  tak ing  an tiretrov iral m edications. A m ong  3 ,6 0 9  partic ip an ts  w ho reported  
ever hav ing  a C D 4  T -lym phocy te  test, 2 ,9 9 6  (83% ) rep o rted  hav ing  th ree or m ore C D 4  T -lym phocy te  tests in  the 12 m on ths 
before the interview . A m o n g  3 ,5 6 7  partic ipan ts w ho repo rted  ever having an  H IV  viral load test, 2 ,9 4 6  (83% ) repo rted  having 
th ree o r m ore H IV  viral load tests in  the  12 m o n th s  before the  interview . A m o n g  3 ,643  partic ipan ts, 4 5 %  needed  H IV  case 
m anagem en t, 33%  needed  m en ta l hea lth  counseling , an d  32%  needed  assistance find ing  den ta l services du rin g  the  12 m o n th s 
before the in terview ; 8% , 13% , and  25%  o f  these partic ipan ts w ho needed  the  services, respectively, had  n o t received these services 
by the  tim e o f  the  interview .
N o n in je c tio n  drugs w ere used for nonm ed ica l purposes by 1 ,117  (31% ) partic ipan ts d u rin g  the 12 m o n th s  before th e  interview , 
an d  122 (3% ) partic ipan ts had  used in jection  drugs for nonm ed ica l purposes. U n p ro tec ted  anal in tercourse was rep o rted  by 527 
(54% ) o f  970  m en  w ho repo rted  having anal sex w ith  a m an  du rin g  the  12 m o n th s  before the  interview . U n p ro tec ted  anal or 
vaginal in tercourse was repo rted  by 176 (32% ) o f  the  553 m en  w ho repo rted  hav ing  anal o r vaginal in tercourse w ith  a w om an  
d u rin g  the  12 m o n th s  before the  interview . U n p ro tec ted  anal o r vaginal in tercourse was rep o rted  by 216  (42% ) o f  the 516  w om en  
w ho repo rted  having anal o r vaginal in tercourse w ith  a m an  d u rin g  the  12 m o n th s  before th e  interview .
Interpretation: T h e  findings in  th is rep o rt ind icate th a t in  2007 , 
m ost persons w ith  H IV  in fec tion  w ho w ere receiving m edical care 
w ere tak ing  an tiretrov iral therapy  an d  had  som e fo rm  o f  h ea lth  
insurance or coverage; however, som e persons w ere n o t receiving
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needed  critical ancillary services, such  as H IV  case m anagem en t o r help  find ing  den ta l services. In  ad d itio n , som e persons living 
w ith  H IV  in fec tion  engaged in  behaviors, such  as u n p ro tec ted  sex, th a t increase the risk for tran sm ittin g  H IV  to sexual partners, 
an d  som e used n o n in jec tio n  or in jection  drugs for nonm ed ica l purposes, w h ich  m ig h t decrease adherence to  an tiretrov iral therapy  
an d  increase hea lth -risk  behaviors.
Public Health Actions: M M P  d ata  can be used to  m o n ito r  the  national H IV /A ID S  strategy  goal o f  increasing access to  care and 
op tim izing  hea lth  ou tcom es am ong  persons living w ith  H IV . Persons in fected  w ith  H IV  w ho are n o t receiving needed  ancillary 
services h igh ligh t m issed o p po rtun ities  for access to  care and  o ther supportive  services, in fo rm atio n  th a t can be used to  advocate for 
add itiona l resources. D ru g  use am ong  persons w ith  H IV  in fec tion  underscores the  co n tin u ed  need for substance abuse trea tm en t 
services for th is p o p u la tio n . In  ad d itio n , p reven tion  services and  program s are needed  to  decrease the n u m b e r o f  H IV -in fec ted  
persons engaging in  u n p ro tec ted  sex. T h e  d a ta  in  this repo rt can be inc luded  in  local, sta te , and  national H IV /A ID S  ep idem iologic 
profiles and  shared  w ith  co m m u n ity  stakeholders. A lth o u g h  d a ta  from  th e  2 0 0 7  M M P  cycle m ig h t n o t be representative o f  all 
persons receiving m edical care for H IV  in fec tion  in  the U n ited  States or in  th e  ind iv idual p ro ject areas, fu tu re  M M P  cycles are 
expected to  y ield w eighted  national estim ates represen ting  all H IV -in fec ted  persons receiving m edical care in  th e  U n ited  States.
Introduction
As o f  D ecem ber 31, 200 8 , an  estim ated  6 6 3 ,0 8 4  persons 
were living w ith  a diagnosis o f  h u m a n  im m unodeficiency  virus 
(H IV ) infection  in  the 40 U .S. states th a t have had  confidential 
nam e-based  H IV  in fec tion  rep o rtin g  since at least January
20 0 6  (1 ). A lth o u g h  H IV  surveillance program s in  the  U n ited  
States collect in fo rm atio n  ab o u t persons w ith  H IV  infection  
and  acquired im m unodeficiency syndrom e (AIDS) (2 ), provide 
an  overview  o f  the  ep idem ic, and  characterize the effects o f  
H IV  in fec tio n , su p p le m e n ta l surveillance p ro jec ts  p rov ide 
add itiona l in fo rm atio n  ab o u t care-seeking behaviors, h ea lth ­
care use, and  o th e r behaviors (3).
In  200 5 , in  response to  an In s titu te  o f  M ed ic ine  rep o rt 
o u tlin in g  the need  for representative d a ta  o n  persons living 
w ith  H IV  in fec tio n  (4), C D C  im p le m e n te d  th e  M edica l 
M o n ito r in g  P ro jec t (M M P ). M M P  was des igned  to  be a 
nationally  representative, popu lation -based  surveillance system  
to  assess clin ical o u tco m es (e.g ., q u a lity  o f  m ed ica l care, 
access to  an d  use o f  H IV  m edical care, an tiretrov iral therapy  
reg im en s, an d  v iro lo g ic  s ta tu s) an d  b eh av io ra l o u tco m es 
(e.g., use o f  p reven tion  services, m ed ica tion  adherence, and 
levels o f  ongo ing  risk behaviors) am ong  persons w ith  H IV  
in fec tion  w ho are receiving m edical care in  the  U n ited  States 
(5). U nw eigh ted  d a ta  from  the in terv iew  co m p o n en t o f  the
2 0 0 7  M M P  d ata  collection  cycle am ong  26  funded  pro ject 
areas are p resen ted  in  this report.
Methods 
Participating Project Areas
D ata  on  patients w ho received m edical care in  2007  (sam pled 
from  Jan u ary  1—A pril 30) were collected d u rin g  June  2 0 0 7 -  
S ep tem ber 2008 . A  previous repo rt described findings from
the 2005  M M P  p ilo t cycle, w h ich  inc luded  10 p ro jec t areas 
(3). A  to ta l o f  26  p ro jec t areas w ere funded  to  co n d u c t data 
collection  activities for the  2 0 0 7  M M P  d ata  co llec tion  cycle 
(Figure 1): C aliforn ia; C hicago , Illinois; D elaw are; Florida; 
G eo rg ia ; H o u s to n , Texas; Illin o is ; In d ia n a ; Los A ngeles 
C o u n ty , C a lifo rn ia ; M a ry la n d ; M assach u se tts ; M ic h ig a n ; 
M ississippi; N ew  Jersey; the sta te  o f  N ew  York; N ew  York 
C ity , N ew  York; N o r th  C a ro lin a ; O re g o n ; P ennsy lvan ia ; 
P h ila d e lp h ia , P en n sy lv an ia ; P u e r to  R ico ; San F rancisco , 
C alifornia; S o u th  C aro lina; Texas; V irgin ia; and  W ash ing ton . 
All 26  pro jec t areas co n d u c ted  interview s an d  m edical record 
abstractions. M edical record abstraction  data  were n o t available 
for inc lusion  in  th is report.
Sampling Method
D eta iled  m ethods for M M P  have been described previously 
(3,5). M M P  collects behavioral an d  clinical in fo rm atio n  from  
a representative sam ple o f  patien ts receiving clinical services 
from  ou tp a tien t H IV  m edical care facilities in  the U n ited  States 
and  P uerto  Rico. M M P  uses a p ro b ab ility  p ro p o rtio n a l to  size 
(PPS) sam pling  design to  ob ta in  cross-sectional p robab ility  
sam ples o f  H IV -in fec ted  adults receiving m edical care in  the 
U n ited  States an d  P uerto  Rico. T h e  M M P  2 0 0 7  sam ple was 
selected in  the follow ing th ree stages:
1. Selection of states. States w ere selected first. A ll 50 states, 
the  D istric t o f  C o lum bia , and  P uerto  Rico (defined as 
p rim ary  sam pling un its [PSUs]) were eligible for selection. 
F rom  these 52 PSU s, 20 were selected using PPS sam pling 
based on  A ID S  prevalence at the  end  o f  2002 . States w ith  
a h ig h e r A ID S  prevalence h ad  a h ig h e r p ro b ab ility  o f  
selection, an d  those w ith  a low er A ID S  prevalence had  a 
low er p robab ility  o f  selection. Six m un ic ipa l jurisd ic tions 
receive se p a ra te  fu n d in g  fo r H IV /A ID S  su rve illance  
(C hicago, Illinois; H o u sto n , Texas; Los Angeles C ounty ,
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C a lifo rn ia ; N ew  Y ork C ity , N ew  York; P h ilad e lp h ia , 
Pennsylvania; an d  San Francisco , C aliforn ia); these areas 
w ere inc luded  w ith  the  sta te for first stage sam pling  and 
com prised  a city-state pa ir u n it. I f  a sta te  inc luded  a city 
w ith  in d e p en d e n t H IV  surveillance au th o rity  (e.g., Texas, 
w h ich  includes H o u sto n , an in d ep en d en tly  fu nded  H IV  
surveillance au th o rity ), se lec tion  o f  the  sta te  in c lu d ed  
selection  o f  the city  (i.e., city-state pairs w ere selected as 
one un it). N ine teen  states (w hich include the six separately 
funded  areas w ith in  those states) and  P uerto  Rico were 
selected from  the  52 PSUs, resu lting  in  26 M M P  project 
areas.
2. Selection of facilities providing HIV medical care. H IV
m edical care facilities w ere selected after sta te  selection. 
Facilities w ere defined  as p rov id ing  H IV  m edical care if  
they provided at least one o f  the following: 1) prescriptions 
for an tiretroviral m edications or 2) C D 4  T -lym phocy te or 
H IV  viral loaded  testing. T h is  defin itio n  was developed 
to  iden tify  providers o f  o ngo ing  H IV  m edical care w ho 
m anaged  H IV  in fec tion  ra the r th a n  referred patien ts to 
an o th er provider. W ith in  each p artic ip a tin g  area, M M P  
sta ff  m em bers com piled  com prehensive lists o f  facilities 
p rov id ing  H IV  m edical care by using various available 
d a ta  sources. T h e  lists w ere developed using  a lis ting  o f  
facilities th a t had  rep o rted  p a tien ts  to  th e  H IV /A ID S  
R e p o rtin g  S ystem  (H A R S ) o r E n h a n c e d  H IV /A ID S  
R eporting  System  (eH A R S), dep en d in g  on  w h ich  system  
was opera tional in  a pro jec t area. (A dditional in fo rm atio n  
o n  H A R S  is available at h ttp ://w w w .cd c .g o v /h iv /s ta ts / 
hasrlink .h tm .) O th e r  additional available data sources were 
used, including  state o r local laboratory  reporting  databases 
(w h ich  in c lu d e  in fo rm a tio n  o n  p ro v id ers  w ho  o rd er 
labo ra to ry  tests), o r p resc rip tion  d rug  lists th a t include 
in fo rm atio n  on  prescribers o f  an tiretrov iral m edications.
T h e  size o f  each facility was de term in ed  by using the 
e s tim a te d  p a t ie n t  lo ad  fo r th e  p o p u la tio n  d e f in itio n  
p e r io d ,  d e f in e d  as th e  4 - m o n t h  p e r io d  d u r in g  
January  1 -A pril 30 , 2007 . T h is  in fo rm atio n  was collected 
based o n  d irect con tac t w ith  the facility. E stim ated  p a tien t 
loads th a t co u ld  n o t be o b ta in e d  fro m  facilities w ere 
ob ta in ed  from  H A R S, eH A R S, o r o th e r sources, such  as 
sta te  o r local labo ra to ry  databases or p resc rip tion  drug  
lists. F rom  these lists, H IV  m edical care facilities were 
sam pled w ith  a likelihood o f  selection p roportional to  their 
estim ated  p a tien t load. Facilities w ith  h igher p a tien t loads 
had  a h igher p ro b ab ility  o f  selection; those w ith  lower 
p a tien t loads had  a low er p robab ility  o f  selection. O n ly  
o u tp a tie n t facilities w ere eligible to  p artic ipa te  in  M M P. 
O u tp a t ie n t facilities w ere defined  as hosp ita l-affilia ted  
clinics, free-standing  clinics, or private physicians’ offices.
Facilities th a t d id  n o t prov ide m edical care (e.g., H IV  
counseling  an d  testing  sites) w ere excluded from  the list 
o f  facilities, as w ere em ergency  d ep a rtm en ts , facilities 
located outside o f  the M M P  areas, federal prisons, facilities 
in  m ilita ry  installations, an d  facilities th a t p rov ided  H IV  
m edical care exclusively to  persons aged <18 years. All 
sam pled  facilities w ere recru ited  to  partic ipa te. I f  a facility 
declined to  partic ipa te  o r was fo u n d  to  be ineligible, th a t 
fa c ility  w as n o t  rep la ce d  w ith  a n o th e r  fac ility  (i.e ., 
su b stitu tio n  o f  facilities was n o t allowed).
3. Selection of patients receiving medical care. Ind iv idual 
p a t ie n ts  w ere  sa m p le d  a f te r  fa c ility  se le c tio n . E ach  
p a r tic ip a tin g  facility  co m p iled  co m p reh en siv e  lists o f  
eligible pa tien ts  seen d u rin g  th e  p o p u la tio n  d e fin itio n  
p erio d . T h e  sam ple  o f  p a tien ts  was se lected  from  the  
com pila tion  o f  all p a tien t lists w ith in  each area. P roject 
areas a t te m p te d  to  r e c ru i t  all s a m p le d  p a t ie n ts  to  
participate .
Participant Recruitment
P a tie n ts  se le c te d  in  th e  th i r d  s tag e  o f  s a m p lin g  w ere 
th en  recru ited  to  partic ipa te  th ro u g h  one o f  tw o strategies: 
en ro llm en t by M M P  s ta ff  or by health -care providers. T h e  
strategy used dep en d ed  on  clin ic needs, p ro jec t area needs, 
In s ti tu t io n a l  R eview  B o a rd  (IR B ) re q u ire m e n ts , a n d  th e  
num ber o f  patients sam pled from  a given facility. For enrollm ent 
by M M P  s ta ff  m em bers, facilities p rov ided  local M M P  s ta ff  
m em bers w ith  con tac t details for patien ts. For en ro llm en t by 
h ea lth -ca re  prov iders, p a tien ts  se lected  to  p a rtic ip a te  w ere 
in itia lly  c o n tac ted  by  th e ir  h ea lth -ca re  p ro v id e r  e ith e r  in  
person , by te lephone , o r by m ail, and  th e n  w ere con tac ted  by 
M M P  s ta ff  m em bers. T h e  sam e p artic ip an t eligibility  criteria 
were used in  all p artic ip a tin g  pro jec t areas: diagnosis o f  H IV  
infection , age >18 years, no  previous p a rtic ip a tio n  in  M M P  
durin g  the cu rren t d a ta  co llection  cycle, receipt o f  m edical 
care at the sam pled  facility d u rin g  the p o p u la tio n  defin ition  
period , an d  ability  to  prov ide in fo rm ed  consent.
Data Collection
M M P  consists o f  tw o com ponents: 1) an in -person  interview  
and  2) m edical record abstraction . M edical record abstraction  
d a ta  w ere n o t availab le fo r in c lu s io n  in  th is  re p o r t. T h e  
questionnaire  is adm in istered  by a tra ined  in terview er using 
com puter-assisted  personal in terv iew  (CA PI) softw are on  a 
lap top  or h an d h e ld  com puter. T h re e  versions o f  the  in terv iew  
questionnaire  (in b o th  E nglish  and  Spanish) w ere developed: 
a s tan d ard  questionnaire , a sh o rt questionnaire , an d  a proxy 
questionnaire . T h e  sh o rt questionnaire  is adm in istered  w hen  
a p a tien t is unab le  to  com plete the  longer s tan d ard  in terv iew
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or w h e n  tra n s la tio n  to  a language  o th e r  th a n  S p an ish  is 
requ ired . T h e  p roxy  q u es tio n n a ire  responses are o b ta in ed  
from  a resp o n d en t w ho serves as a su b stitu te  for a p a tien t w ho 
is too  incapacitated  to  provide responses o r w ho is deceased. 
D a ta  from  interview s com pleted  using the  sh o rt and  proxy 
questionnaires are n o t inc luded  in  this rep o rt because the  data  
are from  abridged  versions o f  the  s tandard  questionnaire , are 
ob ta in ed  u n d e r circum stances th a t vary  from  those for w hich  
the  s tandard  in terv iew  is adm in istered , an d  require different 
in te rp re ta tion .
Persons w ho agreed to  p a rtic ip a te  w ere in terv iew ed in  a 
private location  (e.g., a t h o m e or in  a clinic). T h e  standard  
in terv iew  con ta ined  seven m odules and  to o k  approxim ately  
45 m inu tes to  com plete. (A dditional in fo rm atio n  on  M M P, 
inc lud ing  copies o f  questionnaires, is available at h ttp ://w w w . 
c d c .g o v /h iv /to p ic s /tre a tm en t/M M P /d a ta .h tm .) T h e  m odules 
in c lu d ed  questions on  dem ograph ics , access to  an d  use o f  
h e a lth  care ( in c lu d in g  an tire tro v ira l m ed ica tio n s) , u n m e t 
needs for services, sexual behavior, d rug  an d  alcohol use, use 
o f  p reven tion  services, an d  hea lth  an d  w ell-being.
Statistical Analyses
D a ta  w ere encryp ted  an d  tran sm itted  to  C D C  th ro u g h  a 
secure d a ta  netw ork; statistical softw are was used for cleaning, 
fo r analysis, an d  to  create freq u en cy  tables. D a ta  are n o t 
repo rted  for questions w ith  fewer th a n  five responses. T h is  
repo rt presents the  results o f  a descriptive analysis from  the  26 
p artic ipa ting  p ro jec t areas. N o  statistical tests w ere perform ed.
Measures 
Interview Reference Periods
T h e  tim e  fram es fo r  b e h a v io rs  a n d  se rv ices accessed  
include 1) ever (in  the  p a rtic ip a n t’s lifetim e), 2) at any  p o in t 
since H IV  diagnosis, 3) du rin g  the  past 12 m o n th s  (i.e., the 
12 m o n th s  before th e  in terview ), an d  4) m ost recen t (the 
m o st recen t o ccu rrence  d u r in g  th e  12 m o n th s  before th e  
interview ). A lcohol use du rin g  the past 12 m o n th s  and  past 
30  days, n o n in jec tio n  an d  in jec tion  d rug  use for nonm edical 
purposes d u rin g  the  past 12 m o n th s , and  in jection  d rug  use 
for nonm edica l purposes d u rin g  the  p a rtic ip a n t’s life tim e are 
reported . T h e  tim e fram e used for receipt o f  pneum ococcal 
vaccine is d u rin g  the  5 years before the interview .
Characteristics of Participants
C haracteristics o f  partic ipan ts included  gender, self-reported 
sexual o rien ta tio n , race/ethnicity , age at interview , education  
level, co u n try  or te rrito ry  o f  b irth , tim e since H IV  diagnosis, 
hea lth  insurance o r coverage, and  type o f  coverage. T h e  gender
categories were male, female, and transgender. Participants were 
classified as transgender i f  repo rted  sex at b ir th  an d  cu rren t 
gender as rep o rted  by the  p a rtic ip a n t w ere n o t the  sam e or 
i f  th e y  answ ered  “tran sg e n d e r” to  th e  in te rv iew  q u es tio n  
regarding self-identified  gender. Sexual o rien ta tio n  categories 
w ere heterosexual o r straigh t; hom osexual, gay, or lesbian; 
an d  bisexual. R ace /e th n ic ity  categories w ere n o n -H isp an ic  
black, n o n -H isp an ic  w h ite , H isp a n ic  o r L atino , A m erican  
Indian/A laska N ative, Asian, N ative H aw aiian/Pacific Islander, 
m u ltirac ia l, an d  o ther. Age g roups in c lu d ed  18—24  years, 
25—29 years, 30—34 years, 35—39 years, 4 0 —44  years, 4 5 —49 
years, 50—54 years, 55—59 years, 60—64 years, an d  >65 years. 
E d u ca tio n a l a t ta in m e n t was ca tegorized  as less th a n  h igh  
school, h ig h  school d ip lo m a or G E D  (general educational 
developm ent) credential, and  m ore th a n  h ig h  school. T im e 
since H IV  diagnosis was categorized as >5 years and  <5 years. 
H ea lth  insurance or coverage was categorized as M edicaid , 
M edicare , p rivate  h ea lth  in su ran ce  o r h ea lth  m a in ten an ce  
organization , and  o th e r (includ ing  T rica re /C H A M P U S  and 
V eterans A d m in is tra tio n  coverage). P artic ipan ts cou ld  select 
m ore th a n  one response for insurance or coverage.
Partic ipan ts also were asked i f  they  had  been hom eless at any 
tim e du ring  the 12 m on ths before the interview. M M P  uses the 
M cK inney-V ento defin ition  o f  homelessness, w h ich  categorizes 
persons as hom eless if  they lack a fixed, regular, adequate n igh t­
tim e residence or if  they  have a steady n igh t-tim e residence that 
is 1) a supervised publicly  or privately operated  shelter designed 
to  prov ide tem p o rary  living accom m odation , 2) an in s titu tio n  
th a t provides a tem p o rary  residence for persons in ten d ed  to  be 
in stitu tionalized , o r 3) a p u b lic  or private place n o t designed 
for or o rd inarily  used as a regular sleeping accom m odation  
for h u m a n  beings (e.g., an au tom ob ile  or u n d e r  a bridge).*
P artic ipan ts w ere also asked ab o u t the ir p rim ary  paym en t 
m e th o d  for p resc rip tio n  m ed ica tions for H IV  an d  related 
illnesses, w h e th e r  th e y  h a d  a p p lied  fo r p u b lic  assistance, 
w h eth er they  received any  fo rm  o f  p u b lic  assistance (including 
Social Security  S upp lem enta l Incom e [SSI] o r Social Security 
D isab ility  In su rance  [SSD I]), an d  th e ir  p rim a ry  source o f  
m oney  o r financial su p p o rt. All p ay m en t questions referred 
to  the  12 m o n th s  before the  interview.
Delays in Seeking Medical Care and Use of 
Health-Care Services
P artic ipan ts w ere asked w h e th e r they  delayed th e ir  first visit 
to a doctor, nurse, o r o the r health-care w orker for H IV  m edical 
care for >3 m o n th s after receiving a diagnosis o f  H IV  infection  
and  if  so, the  p rim ary  reason for the  delay. P artic ipants also 
were asked i f  they  h ad  a usual source o f  H IV  m edical care
*Stewart B. McKinney Homeless Assistance Act, 42 U.S.C. §11301, et seq. 1987.
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d u rin g  the 12 m o n th s  before the in terv iew  and  w h e th e r they 
h ad  been ad m itted  to  a m en ta l hea lth  facility  o r received H IV  
care at an  obste trics an d  gynecology clin ic  (w om en  only). 
A dd itiona l m easures o f  health -care use inc luded  the  nu m b er 
o f  p a rtic ip an ts  w ho rep o rted  em ergency  d e p a rtm e n t visits, 
u rgen t care center visits, and  hospitalizations (includ ing  length  
o f  stay), as well as visits to  sexually tran sm itted  disease (STD ) 
clinics an d  testing  for syphilis, gonorrhea, ch lam ydia, herpes, 
genital w arts, nongonococcal u re th ritis (m en only), an d  o ther 
S T D s d u rin g  the  12 m o n th s  before th e  interview.
Antiretroviral Medications and Adherence, CD4 
T-Lymphocyte and HIV Viral Load Testing, 
and Vaccinations
Participants were asked w hether they  had  taken  antiretroviral 
m e d ic a tio n s ,  as w ell as th e i r  re a so n s  fo r  n e v e r  ta k in g  
an tiretrov irals , for n o t cu rren tly  tak ing  an tiretrov irals , and  
for n o t tak ing  th e  last m issed an tiretrov iral dose. P artic ipan ts 
also w ere asked ab o u t the  frequency  o f  C D 4  T -lym phocyte 
co u n t an d  H IV  viral load testing  an d  th e ir  m ost recent C D 4  
T -lym phocy te co u n t an d  H IV  viral load test results d u rin g  the 
12 m on ths before the interview. T h e  C D 4  T-lym phocyte coun t 
categories were as follows: 0—49  ce lls /m m 3, 50—99 ce lls /m m 3, 
100—199 cells/m m 3, 200—349 cells/m m 3, 350—499  cells/m m 3, 
> 500  ce lls /m m 3, an d  “d o n ’t know .” T h e  H IV  v ira l load  
categories w ere as follows: undetectab le, detectable b u t <5,000 
copies/m L , 5 ,0 0 0 —100 ,000  copies/m L , > 1 00 ,000  copies/m L, 
an d  “d o n ’t know .” R eceipt o f  seasonal in fluenza vaccine and 
pneum ococcal p n eu m o n ia  vaccine are also reported .
Unmet Need for Services
P artic ipan ts w ere asked w h e th e r they  needed  and  received 
ancillary  services. For each service, the p a rtic ip a n t’s need  was 
self-perceived an d  de term in ed  by the partic ipan t. A ncillary 
services needed  du rin g  the  past 12 m o n th s  b u t n o t received by 
p artic ipan ts before the in terv iew  were H IV  case m anagem ent, 
m en ta l h ea lth  counseling , assistance find ing  den ta l services, 
so c ia l se rv ic e s  (e .g ., in s u ra n c e  a s s is ta n c e  o r  f in a n c ia l  
counseling), tran sp o rta tio n  assistance, assistance find ing  meals 
or food, assistance find ing  shelter o r housing, assistance finding 
a d o cto r for ongo ing  m edical services, o b ta in in g  education  or 
in fo rm atio n  ab o u t H IV  risk reduc tion , chore or h om em aker 
services, h o m e h ea lth  services (e.g., h o m e n u rs in g  care or 
assistance), adherence su p p o rt services (i.e., professional help 
rem em bering  to  take H IV  m edications on  tim e o r correctly), 
an d  child  care services.
Alcohol and Drug Use
P artic ipan ts w ere asked ab o u t alcohol use d u rin g  the  12 
m o n th s  an d  30 days before the  interview . A  d rin k  was defined
as one can o f  beer, a glass o f  w ine, o r a sh o t o f  liquor. Excessive 
d rin k in g  was defined  as five or m ore drinks per day for m en 
and  four o r m ore drinks per day for w om en.
P a r tic ip a n ts  w ere asked a b o u t th e  use o f  n o n in je c tio n  
and  in jection  drugs. N o n in je c tio n  and  in jection  drugs were 
defined as all drugs, in c lu d in g  legal drugs, th a t w ere n o t used 
for m edical purposes. P artic ipan ts w ere asked ab o u t lifetim e 
(ever) use o f  in jection  drugs (i.e., w h e th e r they  had  ever used 
them ). P artic ipants also w ere asked ab o u t use o f  n o n in jec tio n  
and  in jection  drugs for nonm edica l purposes d u rin g  the 12 
m o n th s  before the  interview . P artic ipan ts could  rep o rt the use 
o f  m u ltip le  types o f  drugs. A dm ission  to  an in p a tie n t d rug 
or alcohol trea tm en t cen ter du rin g  the past 12 m o n th s  also 
was reported .
Sexual Behavior
Participants w ho identified  themselves as m ale or female were 
asked ab o u t the  n u m b e r o f  sex partne rs they  had  du rin g  the 
12 m o n th s  before the interview , the  sex o f  the ir partne rs , and 
the follow ing behaviors: sexual activity  (i.e., anal, vaginal, or 
oral sex) an d  u n p ro tec ted  sexual in tercourse (anal or vaginal 
in te rco u rse  w ith o u t a co n d o m ) w ith  at least on e  p artn e r. 
Participants were also asked abou t the ir m ost recent sex partner, 
inc lud ing  sex o f  th e ir  p a rtn e r  and  know ledge o f  the ir p a rtn e r’s 
H IV  status.
Prevention Activities
P artic ipan ts were asked ab o u t p a rtic ip a tio n  in  group-level 
in te rven tions consisting  o f  at least one organized session w ith  
a sm all g roup  o f  persons to  discuss ways to  p rev en t H IV  
infection . T h e y  also w ere asked ab o u t receip t o f  free condom s 
from  various organizations.
Results
Facility and Participant Response Rates
T h e  m ed ian  facility p artic ip a tio n  rate for the 2 0 0 7  cycle was 
91% , ranging  from  65%  to 100%  by pro jec t area. A  to ta l o f1 5  
p ro jec t areas had  overall facility p a rtic ip a tio n  rates o f  >90% .
From  the 26  partic ipa ting  pro ject areas (Table 1), a sam ple o f  
10 ,503  persons was selected from  582  p artic ip a tin g  facilities. 
O f  these  sa m p le d  p e rso n s , 311 w ere ine lig ib le : 29  w ere 
duplicates, 18 w ere aged <18 years, 63 w ere H IV -negative, 
114 h ad  n o t received care d u rin g  the p o p u la tio n  defin ition  
period , an d  87  w ere ineligible for o th e r reasons, resu lting  in  
a to ta l o f  10 ,192  persons w ho w ere eligible for p artic ipa tion  
in  M M P. T h e  m ed ian  p a tien t p a rtic ip a tio n  rate for the 20 0 7  
cycle was 4 0 %  am ong  eligible patien ts, w ith  a range o f  3%  to 
7 6%  by pro jec t area.
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A  to ta l o f  3 ,9 4 4  partic ipan ts were interview ed. D a ta  for 43 
partic ipan ts w ere excluded because th e  in terview er questioned  
the  valid ity  o f  the  responses. Because behaviors m ig h t change 
after H IV  diagnosis and  the  M M P  in terv iew  p rim arily  focuses 
on  behaviors d u rin g  the past year, in terv iew  d a ta  also were 
excluded for 24  partic ipan ts w ho had  received th e ir  diagnosis 
<12 m o n th s  before in terv iew  an d  234  partic ipan ts for w h o m  
date o f  H IV  diagnosis was m issing o r could  n o t be determ ined  
to  have been at least 12 m on ths before the interview. Therefore, 
th is rep o rt includes d a ta  from  3 ,6 4 3  in terv iew s u sing  the 
s tandard  questionnaire .
Characteristics of Participants
A m o n g  th e  3 ,6 4 3  p a r t ic ip a n ts ,  7 2 %  w ere  m ale , 26%  
w ere fem ale, an d  1%  w ere transgender (Table 2). Forty-n ine 
p ercen t o f  p a rtic ip an ts  rep o rted  th e ir  sexual o rien ta tio n  as 
heterosexual, 4 2 %  as hom osexual, an d  8%  as bisexual. M ost 
partic ipan ts were n o n -H isp an ic  black (40% ) or n o n -H isp an ic  
w h ite  (35% ). T h e  age groups w ith  the  greatest p ro p o rtio n  o f  
partic ipan ts were 4 0 —44  years (20% ) and  4 5 —49  years (22% ). 
A p p ro x im ate ly  h a lf  o f  p a rtic ip a n ts  h ad  m ore th a n  a h ig h  
school education  (51% ), an d  m ost w ere b o rn  in  the U n ited  
States (82% ). T h e  m ajo rity  o f  partic ipan ts (78% ) had  been 
diagnosed w ith  H IV  in fec tion  >5 years previously. A  to ta l o f  
8%  o f  p artic ipan ts  repo rted  th a t they  had  been  hom eless at 
som e tim e d u rin g  the  12 m o n th s  before th e  interview .
O f  th e  3 ,0 4 0  (8 4% ) p a r tic ip a n ts  w h o  re p o rte d  hav ing  
any  o r m u ltip le  types o f  hea lth  insurance or coverage du rin g  
the  past 12 m o n th s , 4 5 %  rep o rted  having  M edicaid , 37%  
repo rted  having private h ea lth  insu rance or coverage th ro u g h  
a h ea lth  m ain tenance  organization , and  30%  repo rted  having 
M ed ica re . (P a rtic ip a n ts  co u ld  select m o re  th a n  on e  type  
o f  m ed ica l in su ran c e  o r coverage response .) P a rtic ip an ts  
p rim a rily  p a id  for p re sc rip tio n  m e d ica tio n s  fo r H IV  an d  
related illnesses th ro u g h  M edicaid , M edicare, o r b o th  (41% ); 
p r iv a te  h e a lth -c a re  coverage (2 5 % ); o r  th e  A ID S  D ru g  
A ssistance P rogram  (25% ) (in fo rm ation  available at h ttp : / /  
h a b .h rsa .g o v /ab o u th ab /p a rtb d ru g .h tm l) . A  to ta l o f  19%  o f  
p artic ip an ts  rep o rted  apply ing  for p u b lic  assistance d u rin g  
the  past 12 m on ths. F orty -n ine  percen t o f  partic ipan ts had  
received pub lic  assistance, inc lud ing  SSI or SSD I, d u rin g  the 
past 12 m on ths, and  4 0 %  rep o rted  th a t SSI or SSD I was the ir 
p rim ary  source o f  m o n ey  o r financial su p p o rt d u rin g  the past 
12 m o n th s  (Table 2).
Delays in Seeking Medical Care and Use of 
Health-Care Services
A m ong  3 ,095  partic ipan ts for w h o m  the  tim e from  receipt 
o f  H IV  diagnosis and  first visit to  a physician , nurse, o r o ther
health -care w orker for H IV  m edical care cou ld  be calculated, 
2 ,4 0 0  (77% ) m ade the ir first visit <3 m o n th s  after receiving 
the diagnosis, 242  (8% ) >3 to  <12 m o n th s  after receiving 
the diagnosis, an d  453  (15% ) >12 m o n th s  after receiving the 
diagnosis. R esponden ts w ho delayed th e ir  first visit for >3 
m o n th s cited  various reasons for the delay (Table 3), includ ing  
n o t w an tin g  to  th in k  ab o u t being  H IV -positive (21% ), feeling 
good and th a t they d id  n o t need to go (18% ), and  n o t believing 
the test result (8% ).
A m o n g  3 ,643  persons in terview ed, 3 ,6 2 6  repo rted  having 
one place in  particular, such  as a physician’s office or clinic, 
w here they  usually  w en t for m ost o f  the ir H IV  m edical care, 
inc lud ing  C D 4  T -lym phocy te and  H IV  viral load testing  o r to 
receive H IV -re la ted  m ed ica tions, du rin g  the past 12 m on ths. 
O f  3 ,5 9 9  persons for w h o m  the  date o f  last visit for m edical 
care was available, 2 ,9 8 2  (83% ) rep o rted  th a t they  h ad  visited 
a health -care p rov ider w ith in  the  past 3 m o n th s . A m o n g  959 
w om en, 244  (25% ) reported  receiving H IV  care at an obstetrics 
and  gynecology clinic du rin g  the past 12 m on ths.
A  to ta l o f  113 (3% ) p a rtic ip a n ts  rep o r te d  hav in g  been 
adm itted  to  a m en tal h ea lth  facility du ring  the past 12 m onths. 
In  ad d itio n , 329  (9% ) p artic ip an ts  rep o rted  th a t th ey  had  
been to  an  em ergency d ep a rtm en t, 105 (3% ) rep o rted  going 
to  an  u rg en t care center, and  252  (7% ) repo rted  having been 
a d m itte d  to  the  h o sp ita l d u rin g  the  p ast 12 m o n th s . T h e  
m ean  repo rted  len g th  o f  stay was 12 days (range: 1—76  days) 
am ong th e  247  partic ip an ts  w ho w ere ad m itted  to  a hosp ital 
and  repo rted  a leng th  o f  stay.
A m o n g  th e  3 ,6 4 3  p a r tic ip a n ts ,  1 ,5 4 5  (4 2 % ) re p o r te d  
being tested  for an  S T D  d u ring  the  past 12 m on ths; the  m ost 
com m on  S T D  tests received were for syphilis (37% ), gonorrhea 
(32% ), chlam ydia (30% ), and  herpes (28% ) (Table 4). A  total 
o f  158 (4% ) o f  the 3 ,643  partic ipan ts repo rted  having  gone 
specifically to  an S T D  clinic for S T D  testing , diagnosis, or 
trea tm en t du rin g  the past 12 m on ths.
Antiretroviral Medications and Adherence
A m ong  all partic ipan ts, 3 ,3 5 9  (92% ) rep o rted  ever taking 
antiretroviral m edications for H IV  infection , and  3,091 (85% ) 
rep o r te d  cu rre n tly  ta k in g  an tire tro v ira ls . A m o n g  th e  542  
partic ipan ts w ho rep o rted  n o t cu rren tly  tak ing  antiretrovirals, 
283  (52% ) rep o r te d  never hav in g  ta k en  th e m . T h e  m ost 
co m m o n  reasons for never tak ing  an tiretrov iral m edications 
were th a t a physician  advised delaying trea tm e n t (47% ), the 
partic ipan t’s C D 4  co u n t o r viral load or b o th  were good (35% ), 
and the partic ipan t felt good and  th o u g h t the m edications were 
n o t needed  (5% ) (Table 5). A m ong  2 5 7  partic ipan ts w ith  a 
h is to ry  o f  an tiretrov iral use, th e  m ost co m m o n  reasons for 
n o t cu rren tly  tak ing  these m edications w ere th a t a physician
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advised de lay ing  tre a tm e n t (2 5 % ), th e  p a r tic ip a n t’s C D 4  
co u n t or viral load  or b o th  w ere good (23% ), the  p artic ip an t 
felt good an d  th o u g h t the  m edications w ere n o t needed  (7% ), 
an d  th e  p a rtic ip an t w orried  ab o u t side effects (6% ) (Table 6).
A m o n g  3 ,0 9 1  p a r t ic ip a n ts  w h o  w ere c u r re n tly  ta k in g  
an tire tro v ira l m e d ica tio n s , 1 ,071 (3 5% ) d id  n o t tak e  all 
an tiretrov iral doses d u rin g  th e  m o n th  before the  interview. 
T h e  m ost co m m o n  reasons given for n o t tak ing  the  last m issed 
dose d u rin g  the past m o n th  w ere fo rge tting  to  take it (38% ), 
a change in  daily  ro u tin e  (12% ), being  busy w ith  o th e r things 
(11% ), and  w an tin g  to  avoid side effects (7% ) (Table 7).
Vaccinations
A m ong  all 3 ,6 4 3  partic ipan ts, 2 ,8 8 8  (79% ) repo rted  th a t 
they  h ad  received a seasonal in fluenza v accination  d u rin g  the 
past 12 m o n th s . A  to ta l o f  2 ,148  (59% ) rep o rted  receiving a 
pneum ococcal p n eu m o n ia  vaccination  du rin g  the  past 5 years.
CD4 T-Lymphocyte and HIV Viral 
Load Testing
T h e  m ost recent C D 4  co u n t am ong  3 ,5 9 2  partic ipan ts w ho 
repo rted  having a C D 4  T -lym phocy te test d u rin g  the  past 12 
m o n th s  was <200 ce lls /m m 3 for 325  (9% ) partic ipan ts, 2 0 0 ­
349  ce lls /m m 3 for 508 (14% ), 3 5 0 -4 9 9  ce lls /m m 3 for 700  
(20% ), > 500 ce lls /m m 3 for 1 ,305 (36% ), an d  u n k n o w n  for 
75 4  (21% ) partic ipan ts (Figure 2). A m ong  3 ,6 0 9  partic ipan ts 
w ho repo rted  ever having  a C D 4  T -lym phocy te  co u n t test, 
2 ,9 9 6  (83% ) rep o rted  hav ing  th ree o r m ore tests in  the past 
12 m on ths. A m ong  3 ,5 4 6  p artic ipan ts  w ho repo rted  having 
an  H IV  viral load  test d u rin g  th e  past 12 m o n th s , the  m ost 
recent viral load was undetectable for 2 ,064  (58% ) participants; 
however, the viral load was u n know n  for 7 2 0  (20% ) (Figure 3). 
A m o n g  3 ,5 6 7  partic ipan ts w ho repo rted  ever hav ing  an  H IV  
viral load test, 2 ,9 4 6  (83% ) rep o rted  hav ing  th ree or m ore 
tests d u rin g  the  past 12 m onths.
Unmet Need for Services
T h e  m o st f re q u en tly  rep o rte d  anc illa ry  services needed  
am ong  the  3 ,643  partic ipan ts w ere H IV  case m anagem ent 
(1 ,650  [45% ] partic ipan ts), m en ta l hea lth  counseling  (1 ,200 
[33% ]), assistance find ing  dental services (1 ,157  [32% ]), social 
services (1 ,124  [31% ]), an d  tra n sp o rta tio n  assistance (899 
[25% ]). P artic ipan ts w ho needed  b u t had  n o t received these 
services by th e  tim e o f  the in terv iew  inc luded  139 (8% ) o f  
those w ho needed  H IV  case m anagem en t, 157 (13% ) o f  those 
w ho needed  m en ta l hea lth  counseling , 294  (25% ) o f those 
w ho needed assistance w ith  f ind ing  den tal services, 210  (19% )
o f  those w ho needed  assistance w ith  social services, and  144 
(16% ) o f  those w ho needed transpo rta tion  assistance (Table 8).
Alcohol and Drug Use
A  to ta l o f  1 ,8 5 8  (5 1 % ) p a r tic ip a n ts  re p o rte d  d rin k in g  
alcohol d u rin g  the  past 12 m on ths, an d  1,518 (42% ) reported  
d rin k in g  alcohol and  the n u m b e r o f  drinks they  consum ed  
on  a typical day d u rin g  the past 30  days. A m ong  those w ho 
d ran k  alcohol du rin g  th e  past 30  days and  w ho also reported  
the n u m b e r o f  d rinks they  consum ed , the  typical average daily 
co n su m p tio n  was 3 .0  drinks. Excessive d rin k in g  (five or m ore 
drinks p er day for m en, four o r m ore for w om en) d u rin g  the 
past 30  days was repo rted  by 500  (14% ) partic ipan ts (408 
m en  an d  92  w om en). A m o n g  these partic ipan ts, the  average 
n u m b e r o f  days o f  excessive d rin k in g  in  the  past m o n th  was 
5.1 for m en  an d  4.1 for w om en.
O v e r a l l ,  1 ,1 1 7  (3 1 % )  p a r t i c ip a n t s  r e p o r te d  u s in g  
n o n in jec tio n  drugs for nonm ed ica l purposes d u rin g  the past 
12 m o n th s . O f  these, 841 (75% ) repo rted  using m arijuana, 
243 (22% ) am yl n itra te  (“p oppers”), 240  (21% ) cocaine th a t 
is sm oked  or sno rted , an d  201 (18% ) crack cocaine (Table 9).
A  to ta l o f 748  (21% ) partic ip an ts  rep o rted  hav ing  ever used 
in jection  drugs for nonm ed ica l purposes, and  122 (3% ) had  
in jected  drugs d u rin g  the  past 12 m on ths . A m ong  the  122 
participan ts w ho injected drugs du ring  the past 12 m onths, the 
drugs m ost frequently  injected w ere crystal m eth am p h etam in e  
by 65 (53% ) partic ipan ts, cocaine (only) by  48 (39% ), hero in  
and  cocaine toge ther by 46 (38% ), an d  h ero in  (only) by  44 
(36% ) (Table 10). A  to ta l o f  139 (4% ) M M P  partic ip an ts  had 
been ad m itted  to  an  in p a tien t d rug  or alcohol trea tm en t center 
du rin g  the  past year.
Sexual Behavior
A m o n g  970  m en  w ho  rep o rted  hav ing  anal in te rcou rse  
w ith  at least one m an  d u ring  the past 12 m on ths , 527  (54% ) 
repo rted  hav ing  u n p ro tec ted  anal in tercourse (Table 11). O f  
1 ,196 m en  w ho had  anal o r oral sex w ith  m en, 960  (80% ) 
repo rted  know ing  th e  H IV  status o f  th e ir  m ost recent m ale 
sex p a rtn e r  (Table 12).
O f  553 m en  w ho reported  having anal or vaginal intercourse 
w ith  at least one w om an  du ring  the past 12 m onths, 176 (32% ) 
reported  having u np ro tec ted  anal or vaginal in tercourse (Table 
11). A m ong  569  m en  w ho had  anal, vaginal, o r oral sex w ith  
w om en , 4 4 6  (78% ) repo rted  know ing  the  H IV  status o f  the ir 
m ost recen t fem ale p a rtn e r  (Table 12).
A m ong  516 w om en  w ho reported  having had  anal o r vaginal 
in tercourse w ith  at least one m an  d u rin g  the  past 12 m on ths, 
2 1 6  (4 2% ) re p o r te d  h av in g  u n p ro te c te d  ana l o r  vag inal
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in tercourse (Table 11), and  428  (83% ) rep o rted  know ing  the 
H IV  status o f  th e ir  m ost recen t m ale p a rtn e r  (Table 12).
Assessment of Prevention Activities
D u rin g  th e  12 m o n th s  before the  interview , 631 (17% ) 
resp o n d en ts  p a rtic ip a te d  in  at least on e  o rgan ized  session 
involving a sm all group  o f  persons (excluding discussions w ith  
friends) to  discuss ways to  preven t H IV . O f  these, 544  (86% ) 
discussed ways to  ta lk  to  a p a rtn e r  ab o u t safe sex, 471 (75% ) 
p rac ticed  ways to  ta lk  w ith  a p a rtn e r  ab o u t safe sex, and  532 
(84% ) discussed ways to  use condom s effectively.
A  to ta l o f  2 ,1 4 8  (59% ) p a r tic ip a n ts  re p o rte d  receiv ing 
free co n d o m s fro m  various o rg an iza tio n s d u r in g  th e  past 
12 m o n th s ; o f  these, 809  (38% ) received co n d o m s from  
H IV /A ID S -fo c u se d  co m m u n ity -b a se d  o rg an iza tio n s , 654  
(30% ) from  an ad u lt H IV /A ID S  specialty  clinic, an d  342  
(16% ) from  a co m m u n ity  hea lth  center o r pub lic  h ea lth  clinic. 
A m o n g  the partic ipan ts w ho repo rted  receiving free condom s, 
1 ,405 (65% ) sta ted  th a t they  h ad  used the  free condom s they 
received, an d  1 ,549  (72% ) sta ted  th a t receiving these free 
condom s m ade th e m  m ore likely to  use condom s d u rin g  sex.
Discussion
Access to Health Care
T h e  benefits o f  trea tm en t provided early in  the course o f  H IV  
in fec tion  are well d o cu m en ted  an d  include increased survival, 
red u ced  m o rb id ity , an d  red u ced  H IV  tran sm iss io n  (6,7). 
O n e  goal o u tlin ed  in  th e  U .S . national H IV /A ID S  strategy 
is to  increase access to  care and  op tim ize hea lth  ou tcom es for 
persons living w ith  H IV  in fec tion  in  the  U n ite d  States. A 
step  tow ard  establish ing this goal is creating  a seamless system  
to im m edia te ly  lin k  patien ts to  co n tin u o u s and  coord ina ted  
quality  care w hen  they  receive a diagnosis o f  H IV  infection . 
O n e  b enchm ark  m easure o f  the  national H IV /A ID S  strategy 
is to  increase from  65%  to 85%  by 2015  the  percen tage o f  
H IV -in fec ted  persons w ho are linked  to  clinical care w ith in  
3 m o n th s  o f  receiving an  H IV  in fec tion  diagnosis (8). In  this 
survey, approx im ate ly  th ree fourths o f  responden ts w ith  valid 
self-reported  dates o f  H IV  diagnosis and  subsequen t in itia tion  
o f  m edical care repo rted  going to  a health-care p rov ider w ith in  
3 m o n th s o f  receiving the diagnosis. D elayed m edical care after 
H IV  diagnosis has been well d o cu m en te d  in  the  literatu re 
(9—15). C u rren t H IV  care guidelines recom m end  H IV  care 
visits every 3 - 6  m o n th s  (16,17). M o n ito rin g  p a tte rn s  o f  care, 
as well as en try  in to  m edical care, am ong  persons w ith  H IV  
is critical an d  will co n tin u e  to  be an im p o rta n t use o f  M M P
data  to  help  m easure progress on  objectives set fo rth  by the 
national H IV /A ID S  strategy.
STD Testing
S T D  in fec tio n  m ig h t suggest recen t o r o n g o in g  sexual 
behaviors th a t could result in  H IV  transm ission (18), and  m any 
S T D s can increase the  risk for acquisition  an d  transm ission  
o f  H IV  (19). Iden tify ing  an d  trea ting  S T D s can reduce the 
p o ten tia l for spread o f  these diseases am ong  groups at h igh  
risk for in fec tion  (i.e., sexual netw orks) (18). C u rren t p rim ary  
care guidelines for persons in fected  w ith  H IV  recom m end  
th a t those at risk for S T D s be screened annually  for syphilis, 
gonorrhea, and  chlam ydia (17). A m ong  the 3 ,643  participants,
1 ,545 (42% ) repo rted  being  tested  for an S T D  d u rin g  the 
p ast 12 m o n th s ; m ost w ere tested  for syphilis, gonorrhea, 
an d  chlam ydia. T h ese  find ings suggest th a t too  few  H IV - 
in fected  persons in  care are being  tested  annually. Screening 
H IV -in fec ted  persons for S T D s is critical to  iden tify  those at 
risk for tran sm ittin g  H IV  and  o th e r S T D s (18). H ealth-care 
providers shou ld  be encouraged  to  test sexually active H IV - 
in fected  patien ts for S T D s annually.
Antiretroviral Medications and Adherence
A dherence to  therapy  is necessary for H IV  viral suppression  
and  to  preven t the  em ergence o f  resistance m u ta tio n s  (16). 
U nd erstan d in g  the  reasons for nonadherence  to  an tiretroviral 
therapy is critical for developing strategies to increase adherence. 
M M P  provides d a ta  to  m easure adherence to  an tiretroviral 
m ed ica tion  regim ens and  specific reasons for nonadherence  
am ong  H IV -in fec ted  persons. T h e  35%  o f  partic ipan ts w ho 
w ere n o t com pletely  ad h e ren t gave various reasons for n o t 
ta k in g  th e  last an tire tro v ira l dose th ey  m issed , in c lu d in g  
fo rg e ttin g  to  do so, a change in  daily  ro u tin e , an d  being  
busy w ith  o th e r  th ings. As recom m ended  in  the cu rren t H IV  
trea tm en t guidelines, strategies to  im prove adherence include 
p resc rib in g  less com plex  reg im ens (e.g., few er pills, fewer 
doses, o r b o th ), using a m u ltid isc ip lina ry  team  approach  to 
care (e.g., nurses, social w orkers, pharm acists, and  m ed ica tion  
m anagers), an d  using clin ician  encoun ters as an o p p o rtu n ity  
to  assess adherence  an d , i f  needed , to  p rov ide  counseling  
(16). O th e r  strategies in c lu d e  p ro v id in g  resources such  as 
pill boxes (16) and  m ed ica tion  alarm s to  rem in d  patien ts to 
take m ed ica tion  (20). D a ta  from  M M P  can increase clinician 
awareness ab o u t the ex ten t o f  an d  reasons for nonadherence 
to  an tiretrov iral m ed ica tions an d  be used in  the developm ent 
o f  new  in te rven tions to  im prove adherence.
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CD4 T-Lymphocyte and HIV Viral 
Load Testing
H IV  C D 4  T -lym phocy te testing  is used to  assess im m u n e 
fu n c tio n , an d  H IV  v ira l lo ad  te s tin g  is used  to  m o n ito r  
the  am o u n t o f  H IV  in  the  b lood  (16); b o th  can be used to 
m o n ito r  access to  and  use o f  care. H IV  viral load  is the  m ost 
im p o rta n t in d ica to r o f  response to  the rapy  (16). T h irty -six  
percen t o f  partic ipan ts repo rted  th a t th e ir  m ost recent C D 4  
co u n t d u rin g  the  past year was > 500 cells/m m 3, and  58%  
repo rted  th a t the ir m ost recent viral load  in  the past year was 
undetec tab le . G uidelines for the  trea tm e n t an d  m anagem en t 
o f  H IV  in fec tion  include m o n ito rin g  C D 4  T -lym phocy te  and 
viral load results every 3—4 m o n th s  after diagnosis (16,17). 
H ow ever, som e h e a lth -ca re  p ro v id ers  p e rfo rm  H IV  v iral 
load testing  every 6 m o n th s  for patien ts w ho are adheren t 
to  an tiretrov iral therapy, w ho have had  the ir H IV  viral load 
suppressed for m ore th a n  2—3 years, an d  w hose clinical and 
im m u n o lo g ic  sta tus is considered  stable (16). E igh ty-three 
percen t o f  M M P  partic ipan ts w ho had  ever had  a C D 4  test 
repo rted  having th ree or m ore C D 4  tests d u rin g  the  past 12 
m on ths , an d  83%  o f  partic ipan ts w ho h ad  ever had  a viral 
load test rep o rted  hav ing  th ree o r m ore viral load tests du rin g  
the  past 12 m on ths , suggesting th a t m ost M M P  partic ipan ts 
received  C D 4  T -ly m p h o c y te  a n d  H IV  v ira l lo a d  te s tin g  
at regu la r in te rva ls as rec o m m en d e d  in  th e  an tire tro v ira l 
trea tm e n t guidelines.
Vaccinations
P u b lic  h e a lth  re c o m m e n d a tio n s  fo r p e rso n s  w ith  H IV  
in fec tion  include vaccination  every year to  p reven t in fluenza 
an d  co n s id era tio n  o f  vacc in a tio n  every 5 years to  p rev en t 
Streptococcus pneumoniae  in fec tion  (21). M M P  d ata  indicate 
th a t ap p ro x im ate ly  7 9 %  o f  p a rtic ip a n ts  received seasonal 
influenza vaccine du ring  the past 12 m onths, and  59%  received 
pneum ococcal vaccine d u rin g  the  past 5 years. A  stu d y  o f  a 
co h o rt o f  H IV -in fec ted  w o m en  in  the  U n ited  States enrolled 
in  the  W o m en ’s In teragency  H ea lth  S tudy  fo u n d  self-reported 
in fluenza vaccination  status ob ta in ed  d u rin g  in terv iew  to be 
55%  for the  2 0 0 6 —20 0 7  in fluenza season and  57%  for the 
2 0 0 7 —2008 in fluenza season (22). T h e  A d u lt an d  A dolescent 
S pectrum  o f  H IV  Disease Project, a m edical record abstraction  
p ro jec t co n d u c ted  am ong  H IV -in fec ted  persons, fo u n d  th a t 
in fluenza vaccination  coverage increased from  28 .5 %  in  the 
1990—1991 in fluenza season to  4 1 .6 %  in  th e  2 0 0 2 —2003 
in f lu e n z a  season  (23 ). T h e  H IV  O u tp a t ie n t  S tudy , also 
a m e d ica l reco rds a b s tra c tio n  p ro je c t c o n d u c te d  a m o n g  
H IV -in fec ted  persons, repo rted  in fluenza rates d u rin g  eight 
in fluenza seasons (1999—2008) an d  fo u n d  th a t vaccination
rates ranged from  25 .8%  to 43 .3%  (24). T h e  data  in  this report 
were ob ta in ed  by self-report ra th e r th a n  from  m edical record 
abstraction , w h ich  m ig h t explain, in  part, the h ig h  p ro p o rtio n  
o f  partic ipan ts w ho h ad  been  vaccinated  in  the past year.
Unmet Need for Services
M M P  d a ta  u ndersco re  the  co n tin u e d  need  fo r ancillary  
H IV  services an d  can be used to  help  determ ine how  resources 
shou ld  be allocated. Use o f  H IV  case m anagem en t has been 
sh o w n  to  increase use o f  an tire tro v ira l m e d ica tio n s  (25), 
and  overall use o f  ancillary services has been associated w ith  
re te n tio n  in  m edical care (26,27) an d  im proved  quality  o f  
life (28). In  this report, the  services needed  d u rin g  the  past 
12 m o n th s  by the largest p ro p o rtio n s  o f  M M P  respondents 
were H IV  case m anagem en t, m en ta l hea lth  counseling , and  
assistance fin d in g  d en ta l services. F ailure to  receive these 
services m ig h t adversely affect h ea lth  behaviors (e.g., result in  
decreased adherence to  m ed ica tio n  regim ens an d  the  ability  
to  stay  engaged in  care) (29).
Alcohol and Drug Use
In je c tio n  d ru g  use can  resu lt in  d irec t tran sm iss io n  o f  
H IV ; in  ad d itio n , the  use o f  alcohol (30,31), n o n in jec tio n  
drugs (31,32), and  in jection  drugs (33) are associated w ith  
risky sexual behav io rs an d  m ig h t co m p lica te  th e  m ed ica l 
m anagem ent o f  H IV  infection  (34—36). Persons w ho use drugs 
for nonm edical purposes m igh t also have o ther cond itions tha t 
increase m o rb id ity  and m orta lity  (16). M M P  data o n  the use o f  
alcohol, non in jection  drugs, and  in jection  drugs can be used by 
persons developing m easures to  preven t alcohol an d  substance 
abuse am ong  those in fected  w ith  H IV . F ifty-one percen t o f  
M M P  partic ipan ts rep o rted  d rin k in g  alcohol d u rin g  the  past 
12 m on ths, 42%  reported  d rink ing  alcohol in  the past 30  days, 
an d  14%  rep o rted  excessive d rin k in g  d u rin g  the  past 30  days. 
In  ad d itio n , 31%  o f  partic ip an ts  repo rted  using n o n in jec tio n  
drugs, and  3%  repo rted  in jecting  drugs d u rin g  the past 12 
m o n th s . C lin ic ians w ho provide m edical care to  H IV -in fec ted  
persons can play a critical role in  help ing  th em  reduce d rug  use 
behaviors th a t increase risk o f  H IV  transm ission  by  screening 
for these behaviors, delivering p reven tion  messages, positively 
reinforcing changes to  safer behavior, and  referring patien ts for 
substance abuse trea tm e n t (18).
Sexual Behavior
Studies have fo u n d  th a t the  prevalence o f  h igh-risk  sexual 
behaviors decreases afte r persons becom e aw are th a t they  
are in fected  w ith  H IV  (37 ,38). R isky sexual behaviors were 
rep o rted  by a h ig h  p ro p o rtio n  o f  M M P  p a rtic ip an ts . T h e
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p ro p o rtio n  o f  M M P  p artic ipan ts w ho had  un p ro tec ted  anal or 
vaginal in tercourse w ith  at least one p a rtn e r  du rin g  the past 12 
m o n th s varied by the  sex o f  the partic ipan ts an d  the ir partners: 
32%  for m ales w ith  fem ale sex p artners , 4 2 %  for fem ales w ith  
m ale sex partners , and  54%  for m ales w ith  m ale sex partners. 
H ow ever, the  p ro p o rtio n  o f  m ales an d  females w ho reported  
th a t they  k new  the H IV  status o f  the ir m ost recent sex p artn e r 
was sim ilar: 80%  for m ales w ho h ad  m ale partners , 78%  for 
males w ho had  fem ale partners , an d  83%  for fem ales w ho had 
m ale partners.
Assessment of Prevention Activities
M easuring  exposure to  an d  use o f  p reven tion  services can 
iden tify  m issed o p p o rtu n ities  for p reven tion  counseling o r the 
need for add itiona l services. Seventeen percen t o f  responden ts 
repo rted  p artic ip a tin g  in  organized group  sessions to  discuss 
H IV  preven tion ; however, 86%  o f  these repo rted  discussing 
ways to  ta lk  to  a p a rtn e r  ab o u t safe sex, 7 5 %  prac ticed  ways 
to  ta lk  w ith  a p a rtn e r  ab o u t safe sex, an d  84%  discussed ways 
to  use condom s effectively. M ale latex condom s, w hen  used 
correctly  an d  consistently, are effective in  p reven ting  H IV  and 
o th e r S T D s (39—41). M M P  m o n ito rs  receipt an d  use o f  free 
condom s and  access to  an d  use o f  o th e r p reven tion  services. 
F ifty -n in e  p e rc e n t o f  p a r tic ip a n ts  re p o r te d  receiv ing  free 
condom s d u rin g  the past 12 m on ths ; o f  these, 65%  reported  
using the  free condom s they  received, an d  7 2 %  repo rted  th a t 
receiving these free condom s m ade th e m  m ore likely to  use 
them . M M P  d ata  can be used to  m o n ito r  exposure to  H IV  
p reven tion  program s and  for efforts to  develop an d  im prove 
local, state, an d  national H IV  preven tion  in te rven tions.
Limitations
T h e  findings p resen ted  in  th is rep o rt are sub ject to  at least 
fou r lim ita tions. First, overall p a tien t p artic ip a tio n  was low  
for the  2 0 0 7  M M P  d a ta  co llec tion  cycle an d  th e  d a ta  are 
unw eigh ted ; therefore, the  results m ig h t n o t be nationally  
o r locally  rep rese n ta tiv e  a n d  are n o t genera lizab le  to  all 
H IV -in fec ted  persons in  care in  the  U n ited  States. Second, 
because the  survey was adm in istered  via in -person  interview s, 
certain  responses m ig h t be subject to  social response bias (e.g., 
u n d errep o rtin g  o f  socially undesirab le behaviors such as d rug 
use or certain  sexual behaviors an d  overreporting  o f  socially 
desirable behaviors such  as adherence to  antiretrovirals and 
co n d o m  use). T h ird , clin ical in fo rm a tio n  (i.e., la b o ra to ry  
values, vaccinations, and  o th e r m edical in fo rm ation ) ob ta ined  
from  the M M P  in terv iew  is self-reported . Because m edical 
record  ab s trac tio n  d a ta  w ere n o t available for inc lu sion  in  
this report, in fo rm atio n  rep o rted  by partic ipan ts d u rin g  the 
in terv iew  could  n o t be com pared  w ith  in fo rm atio n  collected
by m edical record  ab s trac tio n . A nalyses o f  M M P  m edical 
reco rd  a b s tra c tio n  d a ta  are p la n n e d  to  describe  fu lly  the  
clin ical characteristics o f  adu lts  receiv ing m ed ica l care for 
H IV  infection . Finally, in  certa in  instances, s tra tifica tion  by 
certain  characteristics p ro d u ced  num bers th a t w ere too  sm all 
for reliable in te rp re ta tion .
Conclusion
T h ro u g h  ongo ing  data  collection, M M P  will co n tin u e  to 
provide im p o rta n t an d  useful in fo rm atio n  on  behavioral and  
clinical characteristics o f  persons w ith  H IV  in fec tion  w ho are 
receiving H IV  m edical care, inc lud ing  characteristics related to 
p reven tion , seeking m edical care, trea tm en t, receipt o f  needed 
ancillary services, an d  risk behaviors. C e rta in  lim ita tions o f  
M M P  have been addressed in  subsequent data  collection cycles. 
B eginning  w ith  the  2 0 0 9  M M P  d ata  co llec tion  cycle, several 
steps w ere taken  to  im prove p artic ip a tio n  rates. T h e  leng th  
o f  tim e from  selection  o f  patien ts receiving m edical care to 
rec ru itm en t o f  partic ipan ts (con tacting  p atien ts  for interview ) 
was sh o rten ed  to  find  patien ts m ore  qu ick ly  after receipt o f  
care at the M M P  p artic ip a tin g  facilities. C o n tac tin g  patien ts 
m ore  q u ick ly  afte r rece ip t o f  care d u r in g  th e  p o p u la tio n  
defin ition  period m igh t increase the likelihood they have up-to- 
date con tac t in fo rm atio n  an d  facilitate the  ab ility  to  locate 
persons for rec ru itm en t and  p a rtic ip a tio n  in  M M P  Efforts to 
engage H IV  care facilities th a t are selected for p artic ip a tio n  
in  M M P  have also becom e m ore focused on  an d  tailored  to 
the type o f  health -care facility involved. F u tu re  M M P  d ata  are 
an tic ipated  to  provide nationally  representative estim ates o f  
clinical and  behavioral indicators am ong  H IV -infected  persons 
receiving m edical care in  the U n ited  States and  will be used to 
describe com orb id ities o f  persons in fected  w ith  H IV , disease 
m anagem ent, an d  the  quality  o f  care received. T h e  d a ta  also 
will be used to  iden tify  gaps in  services and  allocate local H IV  
services and  resources.
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TABLE 1. Number and percentage of participants, by area —  Medical
Monitoring Project, United States, 2007
Area No.* (%)+










New Jersey 13 (<1)
New York (excluding New York City) 78 (2)
North Carolina 98 (3)
Oregon 211 (6)
Pennsylvania (excluding Philadelphia) 22 (<1)
Puerto Rico 251 (7)
South Carolina 156 (4)
Texas (excluding Houston) 133 (4)
Virginia 154 (4)
Washington 178 (5)
Chicago, Illinois 122 (3)
Houston, Texas 102 (3)
Los Angeles County, California 155 (4)
New York City, New York 249 (7)
Philadelphia, Pennsylvania 184 (5)
San Francisco, California 143 (4)
* N = 3,643. Analyses limited to persons diagnosed with HIV infection for at least
12 months before the interview. 
f Percentages might not add to 100% because of rounding.
TABLE 2. Number and percentage of participants, by selected







Heterosexual or straight 1,791 (49)
Homosexual, gay, or lesbian 1,514 (42)
Bisexual 278 (8)
Race/Ethnicity1
Black, non-Hispanic 1,438 (40)
White, non-Hispanic 1,272 (35)
Hispanic or Latino 699 (19)
American Indian/Alaska Native 19 (<1)
Asian 19 (<1)
Native Hawaiian/Pacific Islander 11 (<1)
Multiracial 119 (3)
Other 61 (2)





40 -44 720 (20)






< High school 790 (22)
High school diploma or GED credential 987 (27)
> High school 1,865 (51)
Country/Territory o f birth
United States 2,984 (82)
Puerto Rico 281 (8)
Mexico 103 (3)
Other 273 (8)
Time since HIV diagnosis
>5 yrs 2,836 (78)
<5 yrs 785 (22)
Homeless** at any tim e during past 12 mos
Yes 280 (8)
No 3,363 (92)
Health insurance or coverage during past 12 mos
Yes 3,040 (84)
No 599 (16)
Type o f health insurance or coverage during past 12 mos++
Medicaid 1,366 (45)
Private health insurance or HMO 1,136 (37)
Medicare 896 (30)
Other§§ 475 (16)
See table footnotes on page 14.
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TABLE 2. (Continued) Number and percentage of participants, by selected
characteristics —  Medical Monitoring Project, United States, 2007
Characteristic No.* (%)+
Primary method of paying for prescription medications for 
HIV and related illnesses during past 12 mos11
Medicaid/Medicare 1,509 (41)
Private health care coverage 896 (25)
AIDS Drug Assistance Program 915 (25)
Not taking any prescription medications for HIV or 187 (5)
related illnesses
Paid for medications themselves (i.e., out of pocket) 194 (5)
Received medications from a public clinic 88 (2)
Received medications from an AIDS service organization 50 (1)
Participated in a clinical trial or research study that 12 (<1)
provided medications 
Applied for public assistance during past 12 mos
Yes 708 (19)
No 2,932 (81)
Received any form of public assistance including SSI or 
SSDI during past 12 mos
Yes 1,798 (49)
No 1,843 (51)
Primary source o f money or financial support during
past 12 mos
SSI or SSDI 1,463 (40)
Salary or wages 1,403 (39)
Spouse, partner, or family 244 (7)
Public assistance 211 (6)
Pension or retirement fund 81 (2)




Abbreviations: AIDS = acquired immunodeficiency syndrome; HIV = human 
immunodeficiency virus; HMO = health maintenance organization; GED = general 
educational development; SSDI = Social Security Disability Insurance; SSI = Social 
Security Supplemental Income.
* Numbers might not add to total because of missing data. Analyses limited to 
persons with diagnosis of HIV infection for at least 12 months before the 
interview. Values exclude categories with fewer than five responses, responses 
of "don't know,” and skipped (missing) responses.
t Percentages might not add to 100% because of rounding.
§ Participants were classified as transgender if sex at birth and gender reported 
by the participant were different or if the participant chose transgender in 
response to the question about self-identified gender.
11 Hispanics or Latinos might be of any race.
**  McKinney-Vento definition of homelessness: living on the street, in a shelter, 
a single-room-occupancy hotel, temporarily staying with friends or family, or 
living in a car. A person is categorized as homeless if that person lacks a fixed, 
regular, adequate night-time residence or has a steady night-time residence 
that is 1) a supervised publicly or privately operated shelter designed to 
provide temporary living accommodation, 2) an institution that provides a 
temporary residence for persons intended to be institutionalized, or 3) a public 
or private place not designed for or ordinarily used as a regular sleeping 
accommodation for human beings (e.g., in an automobile or under a bridge) 
(Stewart B. McKinney Homeless Assistance Act, 42 U.S.C. §11301, et seq; 1987). 
f t  Among 3,040 participants who reported having health insurance or coverage 
during the past 12 months. Participants could select more than one response. 
§§ Includes Tricare/CHAMPUS, Veterans Administration coverage, and insurance 
classified as "other” health insurance.
11 Participants could select more than one response.
TABLE 3. Num ber and percentage o f persons w ho delayed seeking 
medical care for >3 months after receiving HIV diagnosis, by primary  
reason for the delay— Medical Monitoring Project, United States, 2007
Reason No. (%)
Did not want to think about being HIV positive 143 (21)
Felt good, did not need to go 122 (18)
Did not believe test result 54 (8)
Drinking or using drugs 27 (4)
Incarcerated 22 (3)
Unable to get earlier appointment 21 (3)
Hard to find the right doctor 20 (3)
Did not have insurance 19 (3)
Did not know where to go 18 (3)
Participant considered CD4 T-lymphocyte count and viral 13 (2)
load to be good
Denial 10 (1)
Did not have money 9 (1)
Too busy to go 9 (1)
Moved or out of town 6 (<1)
Other* 202 (29)
Total 695 (100)
Abbreviation: HIV = human immunodeficiency virus.
*  Includes responses of "don't know” (N = 2), skipped (missing) responses (N = 
16), and other categories of reasons for delaying treatment that had fewer 
than five responses (N = 184).
TABLE 4. N um ber and percentage o f persons tested for STDs during  
the  past 12 months, by selected STD —  Medical M onitoring  Project, 
United States, 2007





Genital warts (human papillomavirus) 937 (26)
Nongonococcal urethritis 384§ (14)
Abbreviation: STD = sexually transmitted disease.
* Participants could report being tested for more than one STD. 
t Among total number of participants (N = 3,643), unless otherwise noted. 
§ Among participants who reported their sex at birth as male (N = 2,679).
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TABLE 5. Number and percentage of persons who had never taken
antiretroviral medications, by prim ary reason for not taking
medication —  Medical Monitoring Project, United States, 2007
Reason No. (%)
Doctor advised delaying treatment 133 (47)
Participant's CD4 T-lymphocyte count or viral load or 99 (35)
both were good




* Includes skipped (missing) responses (N = 2) and other reasons for never taking 
antiretroviral medication that had fewer than five responses (N = 35).
TABLE 6. N um ber and percentage o f persons not currently taking  
a n tire tro v ira l m ed icatio ns ,* by p rim a ry  reason for n o t tak ing  
medications —  Medical M onitoring  Project, United States, 2007
Reason No. (%)+
Doctor advised delaying treatment 64 (25)
Participant's CD4 T-lymphocyte count or viral load or both 60 (23)
were good
Participant felt good and that medications were not needed 17 (7)
Worried about side effects 15 (6)
No money 10 (4)
No insurance 9 (4)
Drinking or using drugs 9 (4)
Worried about ability to adhere or often forgot 7 (3)
Other5 66 (26)
Total 257 (100)
* Among those with a history of antiretroviral use. 
f Percentages do not add to 100 because of rounding.
§ Includes skipped (missing) responses (N = 2) and other categories of reasons 
for not taking antiretroviral medication that had fewer than five responses 
(N = 64).
TABLE 7. Num ber and percentage o f persons w ho did not take all 
antiretroviral doses during the m onth before the interview, by reason 
for not taking last missed dose —  Medical M onitoring Project, United  
States, 2007
Reason* No. (%)
Forgot to take them 403 (38)
Had a change in daily routine 131 (12)
Was busy with other things 118 (11)
Wanted to avoid side effects 73 (7)
Had problems taking pills at specified times (e.g., with 
meals or on an empty stomach)
27 (3)
Could not afford a refill 22 (2)
Felt depressed or overwhelmed 22 (2)
Could not get to a doctor or clinic 15 (1)
Had too many pills to take 10 (1)
Other1" 371 (35)
Total 1,071 (100)
* Participants could report more than one reason. 
t Categories of reasons that had fewer than five responses.
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TABLE 8. N um ber and percentage o f persons w ho needed ancillary services during the past 12 m onths but did not 
receive them  by the tim e o f the interview , by type o f service needed —  Medical M onitoring Project, United States, 
2007
Service
Persons who needed services* 
No. (%)
Persons who did not receive 
needed service by time of 
interviewt
No. (%)
HIV case management 1,650 (45) 139 (8)
Mental health counseling 1,200 (33) 157 (13)
Assistance finding dental services 1,157 (32) 294 (25)
Social services (e.g., insurance assistance or financial counseling) 1,124 (31) 210 (19)
Transportation assistance 899 (25) 144 (16)
Assistance finding meals or food 663 (18) 88 (13)
Assistance finding shelter or housing 546 (15) 144 (26)
Assistance finding a doctor for ongoing medical services 500 (14) 61 (12)
Education or information on HIV risk reduction 431 (12) 27 (6)
Chore or homemaker services 388 (11) 89 (23)
Home health (e.g., home nursing care or assistance) 383 (11) 59 (15)
Adherence support services 356 (10) 30 (8)
Child-care services 186 (5) 20 (11)
Abbreviation: HIV = human immunodeficiency virus.
* Among total participants (N = 3,643). 
t Among persons who needed the service.
TABLE 9. N um ber and percentage o f persons w ho used noninjection  
drugs*'+ for nonm edical purposes during the past 12 months, by 
type o f drug —  Medical M onitoring  Project, United States, 2007
Drug No. (%)
Marijuana 841 (75)
Amyl nitrate ("poppers”) 243 (22)
Cocaine that is smoked or snorted 240 (21)
Crack cocaine 201 (18)
Crystal methamphetamine ("Tina,”"crank,” or "ice”) 151 (14)
Painkillers (e.g., Oxycontin, Vicodin, or Percocet) 123 (11)
Downers (e.g., Valium, Ativan, or Xanax) 99 (9)
Ecstasy ("X”) 62 (6)
GHB 41 (4)
Heroin/opium that is smoked or snorted 38 (3)
Hallucinogens (e.g., LSD or mushrooms) 25 (2)
Ketamine ("Special K”) 20 (2)
Steroids 19 (2)
Amphetamines ("speed”) 18 (2)
Abbreviations: GHB = gamma hydroxybutyrate; LSD = lysergic acid diethylamide.
* N = 1,117. Participants could report use of more than one noninjection drug. 
t Includes legal noninjection drugs that were not used for medical purposes.
TABLE 10. Num ber and percentage o f persons w ho used injection  
drugs*,+ for nonm edical purposes during the past 12 months, by 
type o f drug used —  Medical Monitoring Project, United States, 2007
Drug No. (%)
Crystal methamphetamine ("Tina, "crank,” or "ice”) 65 (53)
Cocaine only 48 (39)
Heroin combined with cocaine 46 (38)
Heroin only 44 (36)
Crack cocaine 19 (16)
Amphetamines ("speed”) 6 (5)
* N = 122. Participants could report use of more than one injection drug. 
t Includes legal injection drugs that were not used for medical purposes.
TABLE 11. Num ber and percentage o f persons w ho had unprotected  
anal or vaginal intercourse w ith  at least one partner during the past 
12 m onths, by sex o f p a rtic ip a n t* and sex p artn e r —  M edical 
M onitoring Project, United States, 2007
Sex of participant and sex partner^ No.§ (%)
Male with male sex partner (N = 970) 527 (54)
Male with female sex partner (N = 553) 176 (32)
Female with male sex partner (N = 516) 216 (42)
* Participants were classified as male or female, respectively, if sex at birth and 
gender reported by the participant were the same. 
t The categories of male with male sex partner and male with female sex partner 
are not mutually exclusive.
§ Responses from transgender participants not reported because of small 
numbers. Excludes unknown responses.
TABLE 12. N um ber and percentage o f participants w ho reported  
kno w ledg e  o f H IV  status o f m ost recent sex partner, by sex of 
partic ipant* and sex partner —  Medical M onitoring  Project, United  
States, 2007
Sex of participant and sex partner^ No.§ (%)
Male with male sex partner (N = 1,196) 960 (80)
Male with female sex partner (N = 569) 446 (78)
Female with male sex partner (N = 516) 428 (83)
* Participants were classified as male or female, respectively, if sex at birth and 
gender reported by the participant were the same. 
t The categories of male with male sex partner and male with female sex partner 
are not mutually exclusive. Includes participants who reported engaging in 
oral, anal, or vaginal sex.
§ Responses from transgender participants not included because of small 
numbers. Excludes missing responses, "don't know,” "partner hadn't been 
tested,” and refusals to respond.
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FIGURE 1. Participating areas —  Medical M onitoring  Project, United States, 2007
FIGURE 2. Most recent self-reported CD4 T-lymphocyte count* among  
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* N = 3,592. Among participants who reported having a CD4 T-lymphocyte test 
during the past 12 months; excludes refused, skipped, and missing responses.
FIGURE 3. Most recent self-reported HIV viral load* am ong persons 
w ith HIV infection —  Medical Monitoring Project, United States, 2007
<5000
HIV viral load (copies/mL)
* N = 3,546. Among participants who reported having an HIV viral load test 
during the past 12 months; excludes refused, skipped, and missing responses.
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